Guard a Heart- Dr. Douglas Harrington

<p><span class="tx">Dr. Douglas Harrington has over 25 years of experience in the research</span><span class="tx">, development, commercialization, and expansion of innovative</span><span class= "tx"> healthcare technology and services. Dr. Harrington</span><span class="tx">was a member of one of the first heart transplant teams led by</span> <span class="tx">Dr. Jack Copeland from Stanford University. He</span><span class= "tx">-founded one of the first clinical molecular biology laboratories</span><span class="tx"> in the U.S. with the Nebraska Lymphoma Study</span><span class="tx">Group headed by Dr. Jim Armitage. As President and Lab</span><span class="tx">Director of Nichols Institute, Dr. Harrington expanded their molecular</span> <span class="tx">genetics, infectious disease, immunology, </span><span class="tx">cytogenetic, and anatomic pathology offerings. Dr. Harrington</span><span class="tx">led the team that developed one of the first digital microscopes</span> <span class="tx">targeted at minimal residual disease and circulating</span><span class="tx"> tumor cells as the founder and CEO of Clarient. Dr.</span><span class="tx">Harrington also led the turnaround and reinstatement of the federal</span><span class= "tx"> license of Specialty Laboratories, a New York Stock</span><span class="tx">Exchange company, as CEO and Laboratory Director.</span><br /> <span class="tx">Dr. Harrington has developed patents for an automated method</span> <span class="tx">for image analysis of residual cancer cells, a patent covering</span> <span class= "tx">catalytic heavy metal extraction, and a patent-pending</span> <span class="tx">on biomarker assay for diagnosis and classification of cardiac</span> <span class="tx">disease. He has been involved as a director or founder of</span> <span class= "tx">multiple startup companies - from devices to molecular genetics</span> <span class="tx">focusing on immunology, cancer, and cardiology,</span> <span class="tx">where he has taken several new molecular technologies through<